checkAd
    Startseite > Aktien > Werewolf Therapeutics > Nachrichten
    Werewolf Therapeutics Aktie
    4,8500
     
    USD
    -1,62 %
    -0,0800 USD
    Letzter Kurs 02:00:00 Nasdaq
    4,8400
     
    USD
    400 STK
    Geldkurs 15.05.24
    4,8500
     
    USD
    200 STK
    Briefkurs 15.05.24
    ISIN: US95075A1079 · WKN: A3CM1G · SYM: HOWL · USA

    Neueste Nachrichten

    Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
    03.05.24 · globenewswire · Werewolf Therapeutics
    Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
    24.04.24 · globenewswire · Werewolf Therapeutics
    Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
    23.04.24 · globenewswire · Werewolf Therapeutics
    Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting
    05.04.24 · globenewswire · Werewolf Therapeutics
    Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR Platform in Immunology-Based Diseases at AAI Annual Meeting
    04.04.24 · globenewswire · Werewolf Therapeutics
    Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
    07.03.24 · globenewswire · Werewolf Therapeutics
    Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference
    06.03.24 · globenewswire · Werewolf Therapeutics
    Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024
    05.03.24 · globenewswire · Werewolf Therapeutics
    Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook
    08.01.24 · globenewswire · Werewolf Therapeutics
    Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors
    04.01.24 · globenewswire · Werewolf Therapeutics
    Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference
    22.11.23 · globenewswire · Werewolf Therapeutics
    Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
    14.11.23 · globenewswire · Werewolf Therapeutics